Clinical Trial Design
Clinical Trial Phases
Section titled “Clinical Trial Phases”Clinical trials follow a structured progression through phases, each with distinct objectives and patient populations. This sequential approach ensures safety and efficacy are evaluated systematically before regulatory approval.
| Phase | Primary Objective | Participants | Duration |
|---|---|---|---|
| Phase I | Safety, tolerability, pharmacokinetics | 20-100 healthy volunteers (or patients for oncology) | 6-12 months |
| Phase II | Efficacy, optimal dosing, side effects | 100-300 patients with target condition | 1-2 years |
| Phase III | Large-scale efficacy, safety comparison | 1000-3000 patients, multi-center | 2-4 years |
| Phase IV | Post-marketing surveillance, long-term safety | Thousands of patients in real-world settings | Ongoing |
Endpoints
Section titled “Endpoints”Primary endpoints measure the main therapeutic effect (e.g., tumor response rate, HbA1c reduction, pain score improvement). Secondary endpoints capture additional safety and efficacy data (e.g., adverse events, biomarker levels, quality of life scores). Exploratory endpoints generate hypotheses for future studies.
Statistical Analysis
Section titled “Statistical Analysis”Clinical trial analysis relies on several key statistical concepts:
- p-value: Probability of observing results as extreme as the data, assuming null hypothesis is true (typically <0.05 for significance)
- Confidence interval: Range of values within which the true effect likely falls (usually 95% CI)
- Statistical power: Probability of detecting a true effect (typically 80-90% power required)
- Sample size calculation: Based on expected effect size, variability, desired power, and significance level
PK/PD Modeling
Section titled “PK/PD Modeling”Pharmacokinetic (PK) modeling describes how the body affects the drug (absorption, distribution, metabolism, excretion). Pharmacodynamic (PD) modeling describes how the drug affects the body (concentration-effect relationships). PK/PD modeling integrates both to optimize dosing regimens and predict therapeutic outcomes.
Adaptive Designs
Section titled “Adaptive Designs”Adaptive trial designs allow modifications based on interim data without compromising integrity. Common adaptations include sample size re-estimation, dose selection, treatment arm dropping, and endpoint modification. These designs improve efficiency and reduce development costs while maintaining statistical validity.
Key Considerations for Peptide Trials
Section titled “Key Considerations for Peptide Trials”Peptide therapeutics present unique trial design challenges: immunogenicity monitoring (anti-drug antibodies), formulation effects on bioavailability, temperature sensitivity requiring cold chain management, and route of administration influencing PK profiles. Special attention to bioequivalence studies is needed for biosimilar peptide development.